Search for a trial

A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Subjects with Long QT Syndrome type 3.

The primary objective of this study is to evaluate in subjects with LQT3:- The effect of oral eleclazine on mean daytime QTcF interval (in msec) after 24 weeks of treatment with eleclazine (based on standard 12-lead electrocardiogram [ECG] data)The…